Sertraline in coexisting major depression and diabetes mellitus

Psychopharmacology Bulletin

Volumn 33, Issue 2, 1997, Pages 261-264

  Goodnick, Paul J ^a   Kumar, Adarsh ^b   Henry, Joseph H ^b   Buki, Virginia M V ^b   Goldberg, Ronald B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b School of Medicine D79 ^*

Author keywords

Depression; Diabetes mellitus; Prediction; Serotonin; Sertraline

Indexed keywords

SERTRALINE;

ADULT; AGED; ARTICLE; CATECHOLAMINE METABOLISM; CLINICAL ARTICLE; DEPRESSION; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; GLYCOSYLATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; RATING SCALE; RECEPTOR BLOCKING; WEIGHT GAIN;

1-NAPHTHYLAMINE; BLOOD PLATELETS; DEPRESSIVE DISORDER; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SINGLE-BLIND METHOD;

EID: 0030788606     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Aleyassine, H, and Lee, SH. Inhibition of insulin release by substrates and inhibitors of monoamine oxidase. Am. J. Physiol. 222:565-569, 1972.
2. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3d ed., revised. Washington, DC: The Association, 1987.
3. Beck, AT; Ward, DH; Mendelson, M; Mock, J; and Erbaugh, JK. An inventory for measuring depression. Arch. Gen. Psychiatry 4:561-571, 1961.
4. Bressler, R, and Johnson, D. New pharmacological approaches to therapy of NIDDM. Diabetes Care 15:792-805, 1992.
5. Bressler, R; Vargas-Cordon, M; and Lebovitz, HE. Tranylcypromine: A potent insulin secretagogue hypoglycemic agent. Diabetes 17:617-624, 1968.
6. Connolly, VM; Gallagher, A; and Kesson, CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet. Med. 12(5):416-418, 1995.
7. Cooper, AJ, and Ashcroft, G. Potentiation of insulin hypoglycemia by MAOI antidepressant drugs. Lancet I:407-409, 1966.
8. Cooper, AJ, and Keddie, KMG. Hypotensive collapse and hypoglycemia after mebanazine, a monoamine oxidase inhibitor. Lancet 1:1133-1135, 1964.
9. Furman, BL. The hypoglycemic effect of 5-hydroxytryptophan. Br. J. Pharmacol. 50:575-580, 1974.
10. Gavard, JA; Lustman, PJ; and Clouse, RE. Prevalence of depression in adults with diabetes: An epidemiologic evaluation. Diabetes Care 16:1167-1178, 1993.
11. Goodnick, PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin. Pharmacokinet. 27(4):307-330, 1994.
12. Goodnick, PJ; Henry, JH; and Buki, VMV. Treatment of depression in patients with diabetes mellitus. J. Clin. Psychiatry 56:128-136, 1995a.
13. Goodnick, PJ; Henry, J; and Kumar, A. Neurochemistry and paroxetine response in major depression. Biol. Psychiatry 37:417-419, 1995b.
14. Gray, DS; Fujioka, K; Devine, W; and Bray, GA. Fluoxetine treatment of the obese diabetic. Int. J. Obes. Rel. Metab. Disord. 16:193-198, 1992.
15. Greco, AV; Mingrone, G; Capristo, E; De Gaetano, A; Ghirlands, G; and Castagneto, M. Effects of dexfenfluramine on free fatty acid turnover and oxidation in obese patients with type 2 diabetes mellitus. Metabolism 44(Suppl. 2):57-61, 1995.
16. Haeckel, R, and Oellerich, M. Hydrazonopropionic acids, a new class of hypoglycemic substances. Horm. Metab. Res. 11:606-611, 1979.
17. Hakanson, R; Lundquist, I; and Rerup, C. On the hyperglycemic effect of dopa and dopamine. Eur. J. Pharmacol. 1:114-119, 1967.
18. Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23:56-62, 1960.
19. Kaplan, SM; Maas, JW; and Pixley, JM. Use of imipramine in diabetics. JAMA 174:511-517, 1960.
20. Katz, LM; Fochtmann, LF; and Pato, MT. Clomipramine, fluoxetine, and glucose control. Ann. Clin. Psychiatry 3:271-274, 1991.
21. Kumar, AM; Kumar, M; and Krishnaprasad, D. A modified HPLC technique for simultaneous measurement of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in cerebrospinal fluid, platelets, and plasma. Life Sci. 47:1757-1759, 1990.
22. Lustman, PJ; Clouse, RE; and Carney RM. Depression and the reporting of diabetes symptoms. Int. J. Psychiatry Med. 18:295-303, 1988a.
23. Lustman, PJ; Griffith, LS; and Clouse, RE. Depression in adults with diabetes. Diabetes Care 11:605-612, 1988b.
24. Lustman, PJ; Griffith, LS; and Clouse RE. Preliminary results show nortriptyline curbs depression in diabetics. Clin. Psychiatry News, November 1992. p.19. (Currently in press in Psychsomatic Medicine.)
25. Marcus, MD; Wing, RR; and Guare, J. Lifetime prevalence of major depression and its effect on treatment outcome in obese type II diabetic patients. Diabetes Care 15:253-255, 1992.
26. O'Kane, M; Wiles, PG; and Wales, JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet. Med. 11:105-110, 1994.
27. Pestell, RG; Crock, PA; and Ward, GM. Fenfluramine increases insulin action in patients with NIDDM. Diabetes Care 12:252-258, 1989.
28. Scheen, AJ; Paolisso, G; and Salvatore, T. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. Diabetes Care 14:325-332, 1991.
29. True, BL; Perry, PJ; and Burns, EA. Profound hypoglycemia with the addition of a tricyclic antidepressant to maintenance sulfonylurea therapy. Am. J. Psychiatry 144:1220-1221, 1987.
30. Van Loon, BJP; Radder, JK; and Frolich, M. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals. Int. J. Obesity 16:79-85, 1992.
31. Van Praag, HM, and Leijnst, B. Depression, glucose tolerance, peripheral glucose uptake, and their alternatives under the influence of antidepressant drugs of the hydrazine type. Psychopharmacology (Berl.) 8:67-78, 1965.
32. Wickstrom, L, and Pettersson, K. Treatment of diabetics with monoamine oxidase inhibitors. Lancet 2:995, 1964.
33. Wiley, KA; Molyneaux, LM; and Yue, DK. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: Effects of adjunctive dexfenfluramine therapy on glycaemic control. Diabet. Med. 11:701-704, 1994.
34. Wilson, GA, and Furman, BL. Effects of inhibitors to 5-hydroxytryptamine uptake on plasma glucose and their interaction with 5-hydroxytryptophan in producing hypoglycemia in mice. Eur. J. Pharmacol. 78:263-270, 1982.